UBS/CALL/ROCHE GS/450.004/0.025/21.06.24 Stock

Warrant

CROGNU

CH1147771179

Market Closed - Bid/Ask 11:15:00 2024-05-10 EDT After market 23:55:02
0.001 CHF -75.00% Intraday chart for UBS/CALL/ROCHE GS/450.004/0.025/21.06.24 0.016 +1,500.00%

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying ROCHE HOLDING AG
Issuer UBS
CROGNU
ISINCH1147771179
Date issued 2021-12-15
Strike 450 CHF
Maturity 2024-06-21 (31 Days)
Parity 40 : 1
Emission price 0.4 CHF
Emission volume N/A
Settlement physical
Currency CHF

Technical Indicators

Highest since issue 0.49 CHF
Lowest since issue 0.001 CHF
Spread 0.029 CHF
Spread %96.67%

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
234.4 CHF
Average target price
279.4 CHF
Spread / Average Target
+19.19%
Consensus
  1. Stock Market
  2. Warrants
  3. CROGNU Warrant
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW